Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC FTISADTSK acetate | 99.7% | 1029.10 | 1 MG
Supplier: Medchemexpress LLC HYP3146A1MG
FTISADTSK acetate is an endogenous stable signature peptide derived from Trastuzumab, which is monitored by selected reaction monitoring (SRM). It is specifically designed for research purposes and not for human use.
- High purity of 99.66%.
- Intended for research use only.
- Available in various sizes including 1 mg, 5 mg, 10 mg, 50 mg, and 100 mg.
- Comprehensive documentation including Data Sheet, SDS, COA, RP-HPLC, MS, Elemental Analysis Report, and Handling Instructions.
- Detailed instructions for preparing stock solutions in water, along with recommended storage methods and durations to ensure product stability.
- Associated with several screening libraries, such as Metabolism/Protease Compound Library, Anti-Cancer Compound Library, Drug Metabolite Library, Peptide Library, Bioactive Compound Library, Max Bioactive Compound Library Plus, and High-Throughput Bioactive Compound Library.
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?